Clinical Trial Update: Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a triple-drug regimen (atezolizumab, obinutuzumab, and venetoclax) for chronic lymphocytic leukemia, small lymphocytic lymphom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Richter Syndrome
• Small Lymphocytic Lymphoma

Drugs mentioned

• Gazyva (Obinutuzumab)
• Tecentriq (atezolizumab)
• Venclexta (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING